Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXAS stock price vs OPK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OPK's multiple
Needs OPK P/S.
Implied fair value · at EXAS's multiple
Needs EXAS P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXACT SCIENCES CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
OPKO Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
AMARIN CORP PLC\UK
EXAS vs AMRN
Sarepta Therapeutics, Inc.
EXAS vs SRPT
Amphastar Pharmaceuticals, Inc.
EXAS vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
EXAS vs SUPN
Harmony Biosciences Holdings, Inc.
EXAS vs HRMY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EXAS can sustain its 17.7% revenue growth and continue improving margins from -6.4% operating margin and 2.2% EBITDA margin, then EXAS looks preferable to OPK on a relative quality basis because OPK is shrinking, less profitable, and more levered.
The provided valuation framework is incomplete for EXAS, so the pricing gap cannot be cleanly measured on P/E or P/S versus OPK. The only explicit valuation reference is OPK implied price range of $4.76 to $27.40, which leaves EXAS positioned at the top end of the range but without a current price to determine upside or downside.
Supporting Metrics
